Johnson & Johnson is putting behind it the lingering legal problems that stemmed from manufacturing issues that led to recalls some years back.

In the immuno-oncology rivalry between Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo, Keytruda has been running the table. But Opdivo boasts the latest…

A set of women claiming Pfizer’s blockbuster statin Lipitor caused their diabetes have the right to go back to California state court to make their case.

A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…

In one CEO popularity contest, biopharma chiefs are pretty average. But some top execs, including CEOs at Roche, AbbVie and Merck & Co., won kudos.…

The already embattled Valeant has no interest in footing the bill for liability lawsuits over the talc products it bought from J&J.

Inovio is getting closer to producing an effective HIV vaccine. Data from an early-stage clinical study showed that its Pennvax-GP could elicit almost 100%…

Neurocrine’s Ingrezza, fresh off its first FDA approval and aiming for another, just hit a major roadblock.

Johnson & Johnson has signed up as the first sponsor of YouTube's lineup of free original programming for the fall, as exclusive sponsor of a show…